Avalyn Pharma Inc. has 7 Schedule 13D or 13G filings on record since 2026-05-05. 6 holders' latest filing reports 5% or more of voting common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fmr LLC | 13.2% | 5,835,259 | SCHEDULE 13G/A, 2026-08-06 | 2026-06-30 |
| Novo Holdings A/S | 8.8% | 3,883,289 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| SR One Capital Management, LLC | 7.5% | 3,308,649 | SCHEDULE 13D, 2026-05-08 | 2026-05-01 |
| Perceptive Advisors LLC | 6% | 2,675,296 | SCHEDULE 13G, 2026-05-07 | 2026-04-30 |
| Suvretta Capital Management, LLC | 5.6% | 2,503,109 | SCHEDULE 13D, 2026-05-08 | 2026-05-01 |
| Norwest Venture Partners XV, LP | 5.1% | 2,268,404 | SCHEDULE 13G, 2026-08-11 | 2026-06-30 |
Purpose of Transaction (Item 4)
Suvretta Capital Management, LLC
The disclosure in Item 3 above is incorporated herein by reference. The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons' continuing assessments of pertinent factors, including the availability of shares of Common Stock or other securities for purchase at particular price levels, the business prospects of the Issuer, other business investment opportunities, economic conditions, stock market conditions, the attitudes and actions of the board of directors of the Issuer (the "Board") and management of the Issuer, and the availability and nature of opportunities to dispose of securities of the Issuer. The Reporting Persons may discuss items of mutual interest with the Issuer's management, other members of the Board and other investors, which could include items in subparagraphs (a) through (j) of Item 4 Schedule 13D. Depending upon their assessments of the above factors, the Reporting Persons or their affiliates may change their present intentions as stated above and they may assess whether to make suggestions to the management of the Issuer regarding financing, and whether to acquire additional securities of the Issuer (by means of open market purchases, privately negotiated purchases, or otherwise) or to dispose of some or all of the securities of the Issuer under their control. …The first part of Item 4 of the SCHEDULE 13D filed 2026-05-08; the filing has the rest
SR One Capital Management, LLC
The Funds acquired their respective shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, the Funds and other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a …The first part of Item 4 of the SCHEDULE 13D filed 2026-05-08; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-05-05 | Fmr LLC | 11.5% | SCHEDULE 13G |
| 2026-05-07 | Perceptive Advisors LLC | 6% | SCHEDULE 13G |
| 2026-05-08 | Suvretta Capital Management, LLC | 5.6% | SCHEDULE 13D |
| 2026-05-08 | SR One Capital Management, LLC | 7.5% | SCHEDULE 13D |
| 2026-08-06 | Fmr LLC | 13.2% | SCHEDULE 13G/A |
| 2026-08-11 | Norwest Venture Partners XV, LP | 5.1% | SCHEDULE 13G |
| 2026-08-14 | Novo Holdings A/S | 8.8% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for Avalyn Pharma Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.